Krsnaa Diagnost.

Q2 FY26

Krsnaa Diagnost. Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹562

Market cap₹1.9K Cr

P/E19.2

Updated23 Aug 2026

Read4 min read

The short version

Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. Krsnaa Diagnostics expects robust earnings growth, with EBITDA up 18% YoY to Rs.

From Krsnaa Diagnost.'s Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. 600-1,000 crores sales from retail alone.
Revenue growth expected in higher teens percentage over next couple of years.
Q4 FY '26 expected to reach Rs. 100 crore quarterly run rate in retail business due to fast expansion.
Volume growth strategies include introducing wellness packages and advanced test menus, supporting sustainable growth in both PPP and retail channels.
Rajasthan PPP contract expected to kick in FY '27 onwards, providing significant revenue uptick.
Overall revenue expected to grow robustly with retail contributing 8-10% in FY '26, accelerating to 15-20% in next financial year.

2 more points management made on revenue & sales performance

Profitability & Margins

Krsnaa Diagnostics expects robust earnings growth, with EBITDA up 18% YoY to Rs. 60 crore and PAT increasing 22% YoY to Rs. 24 crore in Q2 FY '26.
EPS for Q2 FY '26 improved by 24% YoY to Rs. 7.25.
Retail segment, growing rapidly, is anticipated to contribute 8%-10% of revenue in FY '26, accelerating to 15%-20% in FY '27, enhancing margins and profitability.
The company targets retail revenue to reach 40%-50% in five years, driving overall revenue scale-up.
Operational efficiency and margin expansion are ongoing priorities, supported by technology and cost leadership.

2 more points management made on profitability & margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

For the current fiscal year, excluding Rajasthan, Krsnaa Diagnostics has planned CAPEX of Rs. 150 crores to Rs. 170 crores.
Rs. 80 crores of CAPEX has already been incurred: Rs. 50 crores capitalized and Rs. 30 crores in work-in-progress, mainly for radiology equipment.
Maharashtra MRI centers are in the final stages of implementation, with assets procured on deferred payments (only 20-25% paid initially).
Rajasthan expansion involves establishing around 10 labs by December and 25 labs plus 500 centers by Q4.
Deferred payment and lease models for equipment are being leveraged for capital efficiency.

2 more points management made on capital expenditure plans

Fundraising & Capital Structure

The company is managing borrowings primarily for working capital and maintains tight control over debt.
For further expansion, including Rajasthan and other PPP projects, they are evaluating the most efficient use of capital, which may involve a combination of debt and equity.
No immediate plans or announcements have been made regarding new equity fundraising.

2 more points management made on fundraising & capital structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Maharashtra: 15 MRI centers are under implementation; 10 are near completion and awaiting inauguration.
Rajasthan: Establishing 10 labs soon; target of 25 labs and 500 centers by December, with remaining centers completed in Q4.
Pipeline: Several tenders are in various stages across different states; details kept confidential due to competitive nature.
No recent awarded tenders reported in past 5-6 months; attributed to tender timing and government processes, not reduced tender pipeline.

2 more points management made on order book & pipeline

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹173 Cr, net profit ₹43 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Krsnaa Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

3B Blackbio DX Ltd (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
Unihealth Hospitals Ltd (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Indegene (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
Dr Lal Pathlabs Ltd (Q2 FY26)
Sustained 11%-12% revenue growth without price hikes is planned, driven by increased patient volume and revenue per patient. Key concall takeaways from Dr Lal…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Krsnaa Diagnost. Q2 FY26 results?

Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. Krsnaa Diagnostics expects robust earnings growth, with EBITDA up 18% YoY to Rs.

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

For the current fiscal year, excluding Rajasthan, Krsnaa Diagnostics has planned CAPEX of Rs.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.